Peter Edmund Highfield

Title: The Innovations of Peter Edmund Highfield

Introduction

Peter Edmund Highfield is a notable inventor based in Kent, GB. He has made significant contributions to the field of medical science, particularly in the area of viral polypeptides. With a total of two patents to his name, Highfield's work has implications for diagnostic assays and vaccine formulations.

Latest Patents

Highfield's latest patents include inventions related to viral agents and PT-NANB hepatitis polypeptides. The first patent focuses on post-transfusional non-A non-B hepatitis viral polypeptides, including DNA sequences that encode these polypeptides. It also covers expression vectors containing such DNA sequences and hosts transformed by these vectors. The invention emphasizes the use of these polypeptides in diagnostic assays and vaccine formulations. Similarly, the second patent addresses the same aspects of post-transfusional non-A non-B hepatitis viral polypeptides, reinforcing the importance of his research in this area.

Career Highlights

Highfield is associated with Glaxo Wellcome Inc., a prominent company in the pharmaceutical industry. His work there has allowed him to explore innovative solutions to complex medical challenges. His contributions have been instrumental in advancing the understanding of hepatitis and its implications for public health.

Collaborations

Highfield has collaborated with notable colleagues, including Brian Colin Rodgers and Richard Seton Tedder. These partnerships have likely enhanced the scope and impact of his research, fostering a collaborative environment for innovation.

Conclusion

Peter Edmund Highfield's work exemplifies the intersection of innovation and medical science. His patents reflect a commitment to improving diagnostic and therapeutic approaches to hepatitis. Through his career at Glaxo Wellcome Inc. and collaborations with esteemed colleagues, Highfield continues to contribute to advancements in healthcare.